SEC Form 4 · accession 0000907654-26-000084
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Larry Todd Edwards
Officer — Chief Commercial Officer
Period of report
Aug 24, 2026
Accepted (ET)
Aug 25, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 24, 2026 | A | 100,000 | $0.00 | A | 100,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $102.42 | Aug 24, 2026 | A | 20,000 | A | — | Aug 23, 2036 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.
- F2The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.